Details
Victoza INDICATIONS:
Vikoza® is used for the treatment of insufficiently controlled type II diabetes in adults as a supplement to diet and exercise:
- in monotherapy, when metformin is considered impractical because of intolerance or contraindications;
- in combination with other agents for the treatment of diabetes.
APPLICATION:
To improve gastrointestinal tract tolerance, the starting dose is 0.6 mg liraglutide per day. After at least 1 week, the dose should be increased to 1.2 mg. Some patients are expected to improve after increasing the dose from 1.2 mg to 1.8 mg and, based on treatment responses, to further improve glycemic control after at least 1 week of treatment, the dose can be increased to 1.8 mg. A daily dose above 1.8 mg is not recommended.
Victoza® can be used in addition to metformin therapy already used or a combination of metformin and thiazolidinedione. However, the doses of metformin and thiazolidinedione used may remain unchanged.
The drug Victoza® can be used in addition to the already used therapy with sulfonylurea, a combination of metformin and sulfonylurea or insulin. With concomitant administration of Victose® and sulphonylurea or insulin, the dose of sulphonylurea or insulin should be reduced in order to reduce the risk of hypoglycemia (see section “Application Features”).
Self-monitoring of blood glucose is not required to select the dose of Victosia. However, self-monitoring of blood glucose may be necessary at the beginning of treatment with Victoza® in combination with sulfonylurea or insulin to adjust the dose of sulfonylurea or insulin.
Contraindication:
Hypersensitivity to the active substance or to other components of the drug that are on the excipient list.
Liraglutide is not used for the treatment of patients with type I diabetes or diabetic ketoacidosis.
Liraglutide is not a substitute for insulin.
There is no therapeutic experience in treating patients with Class IV congestive heart failure, as classified by the New York Cardiac Association (NYHA), and therefore liraglutide is not recommended for use in these patients.
Experience in the use of liraglutide in patients with inflammatory bowel disease and diabetic gastroparesis is limited. The use of liraglutide in these patients is not recommended because it is accompanied by temporary adverse reactions from the gastrointestinal tract, including nausea, vomiting and diarrhea.
